LEADERSHIP & STRUCTURE
Amylin is poised for a value inflection year in 2010 by leveraging our deep knowledge and expertise in metabolic diseases, capitalizing on the enormous market opportunity within the diabetes space, advancing our obesity program and continuing to progress along the path to sustained profitability.
The Leadership Team is focused on the following 2010 priorities for Amylin:
- Drive revenue from our currently marketed products BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection
- Obtain approval for, and successfully launch, exenatide once weekly into the large and growing diabetes market, while continuing to advance the clinical trial superiority strategies
- Manage expenses and end the year with sustainable, positive cash flow from operations
- Continue to advance our diabetes and obesity development programs and maximize the value of the Company's deep therapeutic knowledge in peptide research